Cargando…
Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer
As tumor PD-L1 provides signals to anti-tumor PD-1(+) T cells that blunt their functions, αPD-1 and αPD-L1 antibodies have been developed as anti-cancer immunotherapies based on interrupting this signaling axis. However, tumor cell-intrinsic PD-L1 signals also regulate immune-independent tumor cell...
Autores principales: | Gupta, Harshita B, Clark, Curtis A, Yuan, Bin, Sareddy, Gangadhara, Pandeswara, Srilakshmi, Padron, Alvaro S, Hurez, Vincent, Conejo-Garcia, José, Vadlamudi, Ratna, Li, Rong, Curiel, Tyler J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547561/ https://www.ncbi.nlm.nih.gov/pubmed/28798885 http://dx.doi.org/10.1038/sigtrans.2016.30 |
Ejemplares similares
-
Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy
por: Zhang, Deyi, et al.
Publicado: (2021) -
4579 Distinct clinical and immunological responses to αPD-1, kαPD-L1 and αPD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences
por: Garcia, Myrna G, et al.
Publicado: (2020) -
Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice
por: Hurez, Vincent, et al.
Publicado: (2015) -
Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023) -
CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation
por: Reyes, Ryan M, et al.
Publicado: (2021)